Cerus Corp is a biomedical company dedicated to improving blood safety. It specializes in the INTERCEPT Blood System, a technology aimed at reducing pathogens in blood components for transfusion. This system is applied to platelets, plasma, and red blood cells, aiming to make blood transfusions safer by inactivating blood-borne pathogens. Additionally, it offers a solution for producing pathogen-reduced fibrinogen complex, crucial for treating bleeding disorders. Cerus markets its products globally, serving healthcare providers in the U.S., Europe, and beyond, with a focus on enhancing transfusion safety and patient care.